Daratumumab - CISMeF

Preferred Label : Daratumumab;

NCIt synonyms : Anti-CD38 Monoclonal Antibody; HuMax-CD38; Daratumumab Biosimilar HLX15; Daratumumab-fihj;

NCIt definition : A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.;

UNII : 4Z63YK6E0E;

CAS number : 945721-28-8;

Drug name : Darzalex;

Molecule name : JNJ-54767414; HLX15; JNJ 54767414;

Codes from synonyms : 139;

Details

Origin ID

C74007;

UMLS CUI

C2346801;

Automatic exact mappings (from CISMeF team)
- humax-CD38 [MeSH concept]
CISMeF manual mappings
- Daratumumab (substance) [SNOMED CT concept]
See also inter- (CISMeF)
- Product containing daratumumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Daratumumab [LOINC component]
- Daratumumab (substance) [SNOMED CT concept]
- Product containing daratumumab (medicinal product) [SNOMED CT concept]
- daratumumab [MeSH Supplementary Concept]
- daratumumab [MeSH concept]
- daratumumab [ATC Code]
Validated automatic mappings to BTNT
- daratumumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1 [NCIt concept]
is_component_of_chemotherapy_regimen
- Bortezomib/Cyclophosphamide/Daratumumab/Dexamethasone Regimen [NCIt concept]
- Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen [NCIt concept]
- Bortezomib/Daratumumab/Dexamethasone/Thalidomide Regimen [NCIt concept]
- Bortezomib/Daratumumab/Melphalan/Prednisone Regimen [NCIt concept]
- Carfilzomib/Daratumumab/Dexamethasone Regimen [NCIt concept]
- Dara-KRd Regimen [NCIt concept]
- Dara-Pd Regimen [NCIt concept]
- Dara-Rd Regimen [NCIt concept]
- Dara-Vd Regimen [NCIt concept]
- Daratumumab Regimen [NCIt concept]
- Daratumumab/Dexamethasone/Selinexor Regimen [NCIt concept]
- Daratumumab/Lenalidomide Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients